ONO-4578 + ONO-4538 + Oxaliplatin + Levofolinate + Irinotecan + Fluorouracil + Gemcitabine + Nab-Paclitaxel
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Pancreatic Cancer
Conditions
Metastatic Pancreatic Cancer
Trial Timeline
Jan 13, 2021 → Jan 30, 2025
NCT ID
NCT06538207About ONO-4578 + ONO-4538 + Oxaliplatin + Levofolinate + Irinotecan + Fluorouracil + Gemcitabine + Nab-Paclitaxel
ONO-4578 + ONO-4538 + Oxaliplatin + Levofolinate + Irinotecan + Fluorouracil + Gemcitabine + Nab-Paclitaxel is a phase 1 stage product being developed by Ono Pharmaceutical for Metastatic Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT06538207. Target conditions include Metastatic Pancreatic Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Pancreatic Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06538207 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Pancreatic Cancer